论文部分内容阅读
目的:观察纤溶酶辅助治疗脑梗死的疗效和安全性。方法:100例脑梗死患者随机分为两组,对照组50例采用常规治疗,治疗组50例在常规治疗基础上加用纤溶酶治疗。结果:两组治疗后神经功能缺损评分均有明显改善(P<0.05),且治疗组改善程度明显优于对照组(P<0.05)。治疗组总有效率86.0%;对照组总有效率78.0%,差异有统计学意义(P<0.05)。两组均未出现严重出血并发症。结论:纤溶酶辅助治疗急性脑梗死安全有效,值得推广。
Objective: To observe the efficacy and safety of plasmin in the treatment of cerebral infarction. Methods: One hundred patients with cerebral infarction were randomly divided into two groups. The control group (n = 50) was treated with conventional therapy. The treatment group (n = 50) was treated with plasmin on the basis of routine treatment. Results: The scores of neurological deficits in both groups were significantly improved (P <0.05), and the improvement in the treatment group was significantly better than that in the control group (P <0.05). The total effective rate was 86.0% in the treatment group and 78.0% in the control group, the difference was statistically significant (P <0.05). No severe bleeding complications occurred in either group. Conclusion: Plasmin adjuvant treatment of acute cerebral infarction safe and effective, it is worth promoting.